Structured therapeutic education in diabetes: is it time to re-write the chapter on the prevention of diabetic complications?

Endocrine

Volumn 53, Issue 2, 2016, Pages 347-349

  Gazzaruso, Carmine ^a   Fodaro, Mariangela ^a   Coppola, Adriana ^a  

^a Clinical Institute Beato Matteo   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EFFECTIVENESS; DEATH; DIABETES MELLITUS; EDITORIAL; EMPOWERMENT; HEALTH EDUCATION; HUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; RISK REDUCTION; DIABETIC COMPLICATION;

DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS;

EID: 84962776503     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-016-0947-0     Document Type: Editorial

References (20)

1. A. Coppola, L. Sasso, A. Bagnasco, A. Giustina, C. Gazzaruso, The role of patient education in the prevention and management of type 2 diabetes: an overview. Endocrine (2015). doi:10.1007/s12020-015-0775-7
2. P. Gaede, P. Vedel, N. Larsen, G.V. Jensen, H.H. Parving, O. Pedersen, Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Engl. J. Med. 348(5), 383–393 (2003)
3. D. DeWitt, D.C. Dugdale, W.R. Adam, Nonglycemic targets in diabetes. Med. Clin. N. Am. 99(1), 187–200 (2015)
4. J.J. Chamberlain, A.S. Rhinehart, C.F. Shaefer Jr, A. Neuman, Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann. Intern. Med. (2016). doi:10.7326/M15-3016
5. A. Nicolucci, D. Cavaliere, N. Scorpiglione, F. Carinci, F. Capani, G. Tognoni, M.M. Benedetti, A comprehensive assessment of the avoidability of long-term complications of diabetes: a case-control study. SID-AMD Italian Study Group for the Implementation of the St. Vincent declaration. Diabetes Care 19(9), 927–933 (1996)
6. C.K. Wong, W.C. Wong, E.Y. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Macrovascular and microvascular disease in obese patients with type 2 diabetes attending structured diabetes education program: a population-based propensity-matched cohort analysis of Patient Empowerment Programme (PEP). Endocrine (2016). doi:10.1007/s12020-015-0843-z
7. C.K. Wong, W.C. Wong, A.K. Chan, K.L. Chung, F.W. Chan, C.L.K. Lam, Patient Empowerment programme in primary care reduced all-cause mortality and cardiovascular diseases in patients with type 2 diabetes mellitus: a population-based propensity-matched cohort study. Diabetes Obes. Metab. 17(2), 128–135 (2015)
8. C.K. Wong, W.C. Wong, Y.F. Wan, A.K. Chan, F.W. Chan, C.L. Lam, Patient empowerment programme (PEP) and risk of microvascular diseases among patients with type 2 diabetes in primary care: a population-based propensity-matched cohort study. Diabetes Care 38(8), e116–e117 (2015)
9. M.O. Krag, L. Hasselbalch, V. Siersma, A.B.S. Nielsen, S. Reventlow, K. Malterud, N. de Fine Olivarius, The impact of gender on long-term morbidity and mortality of patients with type 2 diabetes receiving structured personal care: a 13 year follow-up study. Diabetologia 59, 275–285 (2016)
10. D. Kent, G. D’EramoMelkus, P.M. Stuart, J.M. McKoy, P. Urbanski, S.A. Boren, L. Coke, J.E. Winters, N.L. Horsley, D. Sherr, R. Lipman, Reducing the risks of diabetes complications through diabetes self-management education and support. Popul. Health Manag. 16(2), 74–81 (2013)
11. B. Zinman, C. Wanner, J.M. Lachin, D. Fitchett, E. Bluhmki, S. Hantel, M. Mattheus, T. Devins, O.E. Johansen, H.J. Woerle, U.C. Broedl, S.E. Inzucchi, EMPA-REG Outcome Investigators, Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New Engl. J. Med. 373(22), 2117–2128 (2015)
12. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33. Lancet 352(9131), 837–853 (1998)
13. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, M.J. Thomason, M.I. Mackness, V. Charlton-Menys, J.H. Fuller, CARDS investigators, Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364(9435), 685–696 (2004)
14. M. Meier, M. Hummel, Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag. 5, 859–871 (2009)
15. J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, TECOS Study Group, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. New Engl. J. Med. 373(3), 232–242 (2015)
16. S. Sapkota, J.A. Brien, J. Greenfield, P. Aslani, A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes: impact on adherence. PLoS One 10(2), e0118296 (2015)
17. C. Gazzaruso, A. Coppola, T. Montalcini, E. Baffero, A. Garzaniti, G. Pelissero, S. Collaviti, A. Grugnetti, P. Gallotti, A. Pujia, S.B. Solerte, A. Giustina, Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine 41(1), 89–95 (2012)
18. C. Gazzaruso, A. Coppola, T. Montalcini, C. Valenti, A. Garzaniti, G. Pelissero, F. Salvucci, P. Gallotti, A. Pujia, C. Falcone, S.B. Solerte, A. Giustina, Erectile dysfunction can improve the effectiveness of the current guidelines for the screening for asymptomatic coronary artery disease in diabetes. Endocrine 40(2), 273–279 (2011)
19. C. Gazzaruso, A. Coppola, C. Falcone, C. Luppi, T. Montalcini, E. Baffero, P. Gallotti, A. Pujia, S.B. Solerte, G. Pelissero, A. Giustina, Transcutaneous oxygen tension as a potential predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. Diabetes Care 36(6), 1720–1725 (2013)
20. L. Fisher, R.E. Glasgow, A call for more effectively integrating behavioral and social science principles into comprehensive diabetes care. Diabetes Care 30(10), 2746–2749 (2007)